InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.660 0.65 (6,500%)+
Announcement
Release
30 Apr 2026 9:53AM
Price at Release
$0.010
Full Release
download
Summary
Alterity Therapeutics Limited is progressing its ATH434 program for treating Multiple System Atrophy, having received significant endorsements from the FDA in support of its planned Phase 3 program. The company, which has a strong financial position with a cash balance of A$44.53 million as of March 2026, is working towards an End-of-Phase 2 meeting with the FDA by mid-2026. Recent presentations at the American Academy of Neurology meeting demonstrated positive clinical efficacy data for ATH434. Alterity has also enhanced its leadership team and continues exploring strategic collaboration opportunities with other pharmaceutical companies. With no major changes in investment or financing cash flows, Alterity remains well-positioned to advance its clinical and regulatory objectives.
Key Points
  • Alterity Therapeutics is advancing its ATH434 program for Multiple System Atrophy (MSA), receiving FDA support for its Phase 3 program.
  • The company plans to have an End-of-Phase 2 meeting with the FDA by mid-2026.
  • Alterity presented new data at the American Academy of Neurology meeting, showing ATH434's efficacy in slowing disease progression.
  • The company has strengthened its leadership team with the appointment of Dr. Daniel Claassen as Chief Medical Advisor and Ms. Ann Cunningham to the Board of Directors.
  • Cash balance at the end of March 2026 was A$44.53 million, with a net cash outflow from operating activities of A$4.73 million for the quarter.
  • Alterity continues discussions with pharmaceutical companies for potential strategic collaborations regarding ATH434.
  • The company hosted a virtual KOL event to highlight ATH434's clinical progress and scientific rationale.
  • Alterity's financial statements showed no significant cash flows from investing activities or financing activities during the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.